We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Sanofi Buys Hemophilia Drugmaker In $11.6B Deal

Law360, New York (January 22, 2018, 7:53 AM EST) -- Sanofi has agreed to buy Bioverativ, a biopharmaceutical business focused on developing treatments for hemophilia and other rare blood disorders, for about $11.6 billion, the companies announced Monday.

The deal comes...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.